Dr. Ian Friedland, M.D. is Chief Medical Officer served as Achaogen Chief Medical Officer since July 2014. Dr. Friedland joined Achaogen from Cubist Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, where he has served as Vice President, Clinical Research since joining Cubist in December 2009. From January 2009 to December 2009, Dr. Friedland served as Chief Medical Officer at Calixa Therapeutics, Inc., a pharmaceutical company acquired by Cubist in December 2009.
So, Dr. Friedland was in Calixa for about a year, leading the clinical trials for Zerbaxa (formely known as CXA-201) which was at Phase II when Cubist acquired the company.
Dr. Friedland continue his work in Cubist until 2014, when Zerbaxa was ready: The drug was approved under the Generating Antibiotic Incentives Now (GAIN) Act and is designated as a Qualified Infectious Disease Product (QIDP) by the FDA.
Dr. Friedland SUCCEED with Zerbaxa, and then has joined Achaogen and leads to the recearch about PLAZOMICIN, which is in Phase III.
"Researchers at the Agriculture Department and the Department of Health and Human Services reported that testing of hundreds of livestock and retail meats turned up the same colistin-resistant bacteria in a sample from a pig intestine in the United States."